L
Lyell Immunopharma, Inc. (LYEL)
NMS – Real Time Price. Currency in USD
11.61
-0.88 (-7.05%)
At close: Jun 26, 2026, 4:00 PM EDT
11.85
+0.24 (2.07%)
After-hours: Jun 26, 2026, 5:31 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
11.61
-0.88 (-7.05%)
At close: Jun 26, 2026, 4:00 PM EDT
11.85
+0.24 (2.07%)
After-hours: Jun 26, 2026, 5:31 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $90.8M significantly exceed its total debt $48.9M, ensuring strong financial flexibility
Total current assets $267.3M exceed Total current liabilities $36.9M, highlighting excellent liquidity
Debt-to-equity ratio (0.2) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$38.6M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 7.23 | 6.05 | 10 | |
| Quick ratio | 7.23 | 5.63 | 10 | |
| Debt to Equity | 0.18 | 0.30 | 9.0 | |
| Debt to Assets | 0.14 | 1.04 | 8.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 85M | 130K | 61K | 36K | 31K |
| Gross Profit | 68M | -20M | -20M | -12M | -10M |
| Operating Income | -192M | -251M | -224M | -204M | -192M |
| Net Income | -183M | -235M | -343M | -274M | -246M |
| EBITDA | -175M | -230M | -204M | -192M | -182M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -28.13 | 29.76 | 5.5 |
| Next quarter | -61.67 | 1.88 | 2.0 |
| Current year | -64.29 | 52.16 | 5.5 |
| Next year | 73302.55 | -4 | 5.5 |
| Weighted average score | 4.6 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -66.66 | 82.84 | 83.94 | -18.56 | 5.5 |
| Y/Y | -71.42 | 53.73 | 40.86 | 29.8 | 7.8 |
| 3y average | -64.62 | -18.09 | -9.29 | 7.89 | 2.3 |
| 5y average | 107.72 | -9.96 | 6.46 | 6.46 | 5.3 |
| Weighted average score | 5.2 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |